54
Participants
Start Date
January 31, 2010
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
Gadopentetate dimeglumine (Magnevist, BAY86-6661)
For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
Hershey
Kiel
Akron
Iowa City
Chicago
St Louis
Houston
Aurora
San Diego
Kansas City
Dresden
Halle
Jena
Lead Sponsor
Bayer
INDUSTRY